製品番号: HY-134476

NF-κΒ activator 1

17 Cited Publications

カスタマーレビュー

Based on 17 publication(s) in Google Scholar

NF-κΒ activator 1 (compound 32) is a potent NF-κΒ activator with an EC₅₀ of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD)2 mRNA expression.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.59%
CAS 番号: 2387524-59-4
分子式: C₁₆H₁₁FN₂O₂S
分子量:314.33

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

NF-κΒ activator 1 構造式

CAS 番号: 2387524-59-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

NF-κΒ activator 1 (compound 32) is a potent NF-κΒ activator with an EC₅₀ of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD)2 mRNA expression^[1].

IC₅₀ & Target^[1]

NF-κB

0.9 μM (EC₅₀)

NF-κB アイソフォーム固有の製品をすべて表示 :

体外実験

NF-κΒ activator 1 (compound 32) (1 μM; 6 hours) induces SOD2 mRNA expression in SH-SY5Y neuroblastoma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 2387524-59-4
性状 Solid
分子量 314.33
分子式 C₁₆H₁₁FN₂O₂S
Color Light yellow to yellow
SMILES

O=C(O)C1=CC=CC(C2=CSC(NC3=CC=CC=C3F)=N2)=C1
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (17)

All RT-PCRWBCell Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Imeta

2026 Jun 14.
J Clin Invest

Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. [Abstract]

2024 Oct 1;134(22):e178628. PMID: 39352749
Carbohydr Polym

A novel strategy with in vivo characterization, extraction, isolation and activity evaluation for discovery of absorbed anti-inflammatory oligosaccharides from Zhu-Ling decoction. [Abstract]

2024 Oct 15:342:122422. PMID: 39048245
Chem Eng J

2024 May 1, 487, 150501.
Cell Death Dis

BRISC is required for optimal activation of NF-κB in Kupffer cells induced by LPS and contributes to acute liver injury. [Abstract]

2023 Nov 15;14(11):743. PMID: 37968261

NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Nov 15;14(11):743. [Abstract]

WT and Abro1 KCs cells were pretreated with NF-κB activator 1 for 6 hours, followed by treatment with 100 ng/ml LPS for 3 hours. CBA analysis was used to analyze the expression of TNF-α and IL-6.
Oncogene

Monoacylglycerol lipase blockades the senescence-associated secretory phenotype by interfering with NF-κB activation and promotes docetaxel efficacy in prostate cancer. [Abstract]

2024 Sep;43(38):2835-2849. PMID: 39155296

NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]

NF-κΒ activator 1 (1 μM for 48 h). Immunoblot detection of NF-κB p105/50, NF-κB p100, IκBα, Phospho-IκBα (Ser32/36), NF-κB p65 and phospho-NF-κB p65 (Ser536) in Over-MGLL and Vector PC3 cells.

NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]

NF-κB activator 1 (1 μM for 48 h). Staining for aging-related β-galactosidase.

NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]

Cell proliferation assays of MGLL-overexpressing stable cells, docetaxel (10 nM), and NF-κB activator 1 (1 μM, 48 h) treated with these agents.

NF-κΒ activator 1 purchased from MedChemExpress. Usage Cited in: Oncogene. 2024 Sep;43(38):2835-2849. [Abstract]

Immunoblotting results of MGLL overexpression stable cells treated with docetaxel (10 nM) and NF-κB activator 1 (1 μM, 48 h).
J Nutr Biochem

Quercetin reverses DEHP-induced ZBP1-mediated PANoptosis in thymus by targeting NF-κB to regulate the TNF-α/ROS signaling pathway. [Abstract]

2026 May 25:110423. PMID: 42191001
J Mol Cell Cardiol

Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]

2025 May:202:133-143. PMID: 40122157
J Immunol

HMGB1 inhibits the IFN-γ-induced PD-L1 expression in NSCLC. [Abstract]

2025 Jun 28:vkaf125. PMID: 40580518
Clin Exp Immunol

Docosahexaenoic acid mitigates experimental autoimmune prostatitis by inhibiting Th17 cell differentiation via the PPARγ/NF-κB/IL-17A pathway. [Abstract]

2025 Jan 21;219(1):uxaf055. PMID: 40887935
Int J Med Sci

Artemisia argyi-enhanced Mesenchymal Stem Cell Exosomes Alleviates Inflammation in C28/I2 Chondrocytes by inhibiting NF-κB. [Abstract]

2026 Feb 18;23(3):1092-1104. PMID: 41799761
Toxicol Appl Pharmacol

ADAMTS7 selective inhibitor BAY-9835 alleviates acute myocardial infarction by suppressing the NF-κB-mediated pyroptosis. [Abstract]

2026 Aug:513:117836. PMID: 42061659
Mol Oral Microbiol

Ginsenoside Compound K Plays an Anti-Inflammatory Role in Gingival Epithelial Cells Stimulated With Porphyromonas gingivalis by Regulating Pyruvate Kinase M2. [Abstract]

2026 Aug;41(4):216-226. PMID: 41923291
J Cancer

ADAMTS7 Enhances Gastric Cancer Growth and Metastasis by Triggering the NF-κB Signaling Pathway. [Abstract]

2025 Jan 1;16(3):1008-1019. PMID: 39781347
Behav Brain Res

CX3CR1 mediates Motor Dysfunction in Mice through 5-HTR2a. [Abstract]

2024 Mar 12:461:114837. PMID: 38145872
Thromb J

Liquiritin mitigates lower extremity deep vein thrombosis by inhibiting inflammation and oxidative stress via the NF-κB signaling pathway. [Abstract]

2025 May 20;23(1):51. PMID: 40394684
Anim Reprod Sci

HSP72 alleviates heat stress-induced oxidative damage in boar Sertoli cells through modulating the AGE-RAGE/NOX4/NF-κB axis. [Abstract]

2026 Jun:289:108144. PMID: 41740418

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (318.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1814 mL

15.9069 mL

31.8137 mL

5 mM

0.6363 mL

3.1814 mL

6.3627 mL

10 mM

0.3181 mL

1.5907 mL

3.1814 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (15.91 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (6.62 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (6.62 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Mathew B, et al. Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS [published online ahead of print, 2020 Oct 22]. Eur J Med Chem. 2020;112952. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1814 mL	15.9069 mL	31.8137 mL	79.5343 mL
	5 mM	0.6363 mL	3.1814 mL	6.3627 mL	15.9069 mL
	10 mM	0.3181 mL	1.5907 mL	3.1814 mL	7.9534 mL
	15 mM	0.2121 mL	1.0605 mL	2.1209 mL	5.3023 mL
	20 mM	0.1591 mL	0.7953 mL	1.5907 mL	3.9767 mL
	25 mM	0.1273 mL	0.6363 mL	1.2725 mL	3.1814 mL
	30 mM	0.1060 mL	0.5302 mL	1.0605 mL	2.6511 mL
	40 mM	0.0795 mL	0.3977 mL	0.7953 mL	1.9884 mL
	50 mM	0.0636 mL	0.3181 mL	0.6363 mL	1.5907 mL
	60 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3256 mL
	80 mM	0.0398 mL	0.1988 mL	0.3977 mL	0.9942 mL
	100 mM	0.0318 mL	0.1591 mL	0.3181 mL	0.7953 mL

Keywords

NF-κΒ activator 1

17 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

NF-κΒ activator 1

Antioxidant Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Pain-Related Compound Library

Highly Selective Activators Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 NF-κΒ activator 1

NF-κB アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (17)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

NF-κΒ activator 1

Antioxidant Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Pain-Related Compound Library

Highly Selective Activators Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 NF-κΒ activator 1

NF-κB アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (17)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

NF-κΒ activator 1 関連分類

HY-134476 関連分類